The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Business
  • Tech
  • Bio
  • Companies
Sun, July 3, 2022 | 17:24
Companies
Investors to flock to makers of test kits, vaccines
Posted : 2021-11-28 16:31
Updated : 2021-11-28 17:11
Print Preview
Font Size Up
Font Size Down
                                                                                                 A gas station attendant stands next to a newspaper headline in Pretoria, South Africa, Saturday. AP-Yonhap
A gas station attendant stands next to a newspaper headline in Pretoria, South Africa, Saturday. AP-Yonhap

By Kim Yoo-chul

The Korean stock market is awaiting updates over the Omicron variant of the coronavirus. As the local stock market correlates very closely with moves in major indexes, investors are highly likely to react negatively following the U.S. and European stock markets' falls last week.

Crude oil prices and Treasury yields plunged on Wall Street as a new strain ― known as the Omicron variant ― prompted fears of renewed social restrictions. As the market slides, investors are being advised to move their money into stocks of companies related to vaccine production, work-from-home, food delivery and games, analysts said, Sunday.

Last week on Wall Street, Pfizer partner BioNTech and Moderna made gains on the back of the Omicron variant. Moderna said it is testing to see if a higher booster dose of its vaccine would provide protection against the new virus strain.

[ANALYSIS] Omicron variant to sink travel, leisure stocks
[ANALYSIS] Omicron variant to sink travel, leisure stocks
2021-11-28 16:31  |  Markets

In sync with advances by vaccine-producing companies, Samsung Biologics and Seegene are expected to be visible gainers until any scientific findings are found proving the effectiveness of existing COVID-19 vaccines in defending against the Omicron variant.

                                                                                                 A gas station attendant stands next to a newspaper headline in Pretoria, South Africa, Saturday. AP-Yonhap
A departures billboard displays flights to Lisbon, Cape Town, Zurich and Frankfurt at the airport in Munich, Germany, Saturday. EPA-Yonhap

Pfizer and Moderna said they were working on the development of Omicron COVID-19 variant vaccines, though FDA approval will take several months. Samsung Biologics is Moderna's CDMO partner under which the Samsung affiliate manufactures the latter's COVID-19 vaccines at its Songdo plant in Incheon, with substances and core materials provided by the U.S.-based biotech firm.

Last week, COVID-19 test-kit leader Seegene's share price spiked 17.1 percent to end at 71,900 won, with Labgenomics soaring 24.6 percent to 31,400 won per share. SK Bioscience, a local COVID-19 vaccine developer and one of the country's leading CDMO companies, saw a 9.41 percent rise to 279,000 won, according to data by Korea Exchange (KRX), the country's top bourse operator.

The so-called "lockdown beneficiaries," COVID-19 testing and vaccine companies, have been gaining. But their growth momentum has been questioned lately, mostly because of massive vaccination efforts by the Korean government.

"News of the Omicron COVID-19 variant is just a bad factor in terms of investor sentiment, as supply chain troubles have been continuing. But the market is awaiting developments such as factory closures. As no such announcements have been made yet, I would say market volatility would be limited," said Seo Sang-young, an analyst at Mirae Asset Securities.

"Again, we have to find out if this new variant will cause more lockdowns or even more economic depression around the world. Before that, investors are advised to assess stocks based on short-term trading view."

Other than "sentimental factors," some analysts said blind investment in the stocks of local vaccine makers aren't a guaranteed payoff, as the country's major biopharmaceutical firms are in boxed progress as they respond only to manufacturing COVID-19 vaccines.


Emailyckim@koreatimes.co.kr Article ListMore articles by this reporter
 
LG
  • Forum revisits lives of first-generation of Koreans in Hawaii
  • Heatwave alert issued nationwide
  • Korean studies and K-vibe
  • EV fires could hinder transition to eco-friendly vehicles
  • Institutional investors dump Samsung shares amid macroeconomic uncertainty
  • '97 group' lawmakers throw hats into DPK leadership race
  • Russia's messages with missiles tell West to back off
  • Top economic policymakers of Korea, US discuss Russian oil price cap
  • Shifting abortion laws cause confusion for patients, clinics
  • NY overhauls handgun rules in effort to preserve some limits
  • Park Eun-bin plays genius lawyer in 'Extraordinary Attorney Woo' Park Eun-bin plays genius lawyer in 'Extraordinary Attorney Woo'
  • 'Top Gun: Maverick' tops local box offices for 9 consecutive days 'Top Gun: Maverick' tops local box offices for 9 consecutive days
  • K-pop group aespa to attend UN meeting on sustainable development K-pop group aespa to attend UN meeting on sustainable development
  • 'Elvis' has a lot in common with K-pop music industry: director Baz Luhrmann 'Elvis' has a lot in common with K-pop music industry: director Baz Luhrmann
  • YG Entertainment founder's younger brother reinstated as co-CEO YG Entertainment founder's younger brother reinstated as co-CEO
DARKROOM
  • Afghanistan earthquake killed more than 1,000

    Afghanistan earthquake killed more than 1,000

  • Divided America reacts to overturn of Roe vs. Wade

    Divided America reacts to overturn of Roe vs. Wade

  • Namaste: Yogis to celebrate International Yoga Day

    Namaste: Yogis to celebrate International Yoga Day

  • Poor hit harder by economic crisis

    Poor hit harder by economic crisis

  • Roland Garros 2022

    Roland Garros 2022

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group